Skip to content

Posts tagged ‘neurodegeneration’

Avoiding gibberish when assessing for dementia

In her runner-up article for our 2017 Max Perutz Science Writing Award Nadine Mirza, a PhD student at the University of Manchester, explains why changes are needed to a routine test for diagnosing dementia, unbiased by language or culture, to prevent incorrect diagnoses.

Have you heard the saying “No ifs ands or buts”? Associated with grannies and teachers, you’d be hard pressed to find someone who hasn’t. It’s also a saying used in the ACE, a test implemented across the UK to detect dementia. An individual has to read the saying out loud with correct pronunciation. When directly translated into Urdu it loses meaning and becomes gibberish and reading out gibberish isn’t a smooth task. Even a fluent Urdu speaker might fail. But would we attribute that to dementia? Apparently, yes.

Read more

Sharing data to speed up dementia research

By studying large groups of people over time, researchers are trying to spot early signs of diseases, including dementia. As large studies are huge undertakings it makes sense to check what’s already out there before setting up a new one – but this is no easy task. A new tool aims to help by collecting neurodegenerative disease cohort studies in one place. Professor Dag Aarsland, a leading dementia researcher, put the JPND Global Cohort Portal through its paces.

I study a specific type of dementia called dementia with Lewy bodies. Despite being the second most common form of neurodegenerative dementia, we know little about how it progresses. This information is important to inform diagnosis and research.

Collating existing data

In 2014, I led an international working group supported by the EU Joint Programme for Neurodegenerative Disease Research (JPND). It focused on solving some of the challenges of using cohorts – studies involving large groups of people – for research on dementia with Lewy bodies.

Our working group agreed that we need to combine data, collected in past and existing cohort studies, to define criteria for early diagnosis of this common type of dementia. To do this, we need a full view of what data is already out there, something that the new JPND Global Cohort Portal offers.

Read more

Dementia: why don’t we have any treatments yet?

Alois Alzheimer first described his eponymous disease a century ago, but there are still no effective treatments. For World Alzheimer’s Day, Professor Bart de Strooper, Director of the UK Dementia Research Institute, asks why that is, and tells us how that might all be about to change.

Bart de Strooper UK Dementia Research Institute

Professor Bart de Strooper

In the early 1900s, a German neurologist called Alois Alzheimer became obsessed with studying an Asylum patient in her 50s, who had started to show unusual behavioural changes, including short-term memory loss. After her death he examined her brain and discovered structures known as amyloid plaques and neurofibrillary tangles – the hallmarks of what became known as Alzheimer’s disease.  So why, when we’ve known about the disease for so long, are there still no treatments? Read more